ECSP993003A - USE OF PEG - IFN -ALPHA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C - Google Patents

USE OF PEG - IFN -ALPHA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C

Info

Publication number
ECSP993003A
ECSP993003A ECSP993003A ECSP993003A EC SP993003 A ECSP993003 A EC SP993003A EC SP993003 A ECSP993003 A EC SP993003A EC SP993003 A ECSP993003 A EC SP993003A
Authority
EC
Ecuador
Prior art keywords
ifn
peg
treatment
chronic hepatitis
ribavirine
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Friederike Zahm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42043992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP993003(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Priority to ECSP993003 priority Critical patent/ECSP993003A/en
Publication of ECSP993003A publication Critical patent/ECSP993003A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona el uso de conjugados de PEG-IFN-a en asociación con Ribavirina para la fabricación de fármacos para el tratamiento de las infecciones por hepatitis C crónica. Además, la presente invención proporciona un método para tratar infecciones por hepatitis C crónica en pacientes que necesiten de tal tratamiento que comprende la administarción de una cantidad de un conjugado de PEG-IFN-a en asociación con una cantidad de Ribavirina efectiva para tratar la hepatitis C.The present invention provides the use of PEG-IFN-a conjugates in association with Ribavirin for the manufacture of drugs for the treatment of chronic hepatitis C infections. Furthermore, the present invention provides a method of treating chronic hepatitis C infections in patients in need of such treatment comprising administering an amount of a PEG-IFN-a conjugate in association with an amount of Ribavirin effective in treating hepatitis C.

ECSP993003 1999-06-08 1999-06-08 USE OF PEG - IFN -ALPHA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C ECSP993003A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP993003 ECSP993003A (en) 1999-06-08 1999-06-08 USE OF PEG - IFN -ALPHA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP993003 ECSP993003A (en) 1999-06-08 1999-06-08 USE OF PEG - IFN -ALPHA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C

Publications (1)

Publication Number Publication Date
ECSP993003A true ECSP993003A (en) 2000-01-27

Family

ID=42043992

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP993003 ECSP993003A (en) 1999-06-08 1999-06-08 USE OF PEG - IFN -ALPHA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C

Country Status (1)

Country Link
EC (1) ECSP993003A (en)

Similar Documents

Publication Publication Date Title
CO5050297A1 (en) USE OF PEG-IFN-ALFA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C
DE60121988D1 (en) COMBINATION THERAPY WITH ANTIDIBLE AND ANTICONVULSIVE AGENTS
ATE309798T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIDIOL DERIVATIVES
TWI317735B (en) Methods and compositions for treating hepatitis c virus
CO4290346A1 (en) Azithromycin Controlled Release Dosage Forms
AR036321A1 (en) METHOD AND PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF LATE APPEARANCE DYSCINESIA.
ECSP993003A (en) USE OF PEG - IFN -ALPHA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C
FR2839450B1 (en) MEDICAMENT PREPARATION IN PARTICULAR FOR THE TREATMENT OF HERNIES DISCALES
CY1106388T1 (en) THERAPY OF HEPATITIS C WITH THYMOSIN, INTEPHON, AND RIBAVIRIN
AR057746A1 (en) PEG-IFN ALFA AND RIBAVIRINE FOR THE TREATMENT OF HEPATITIS B VIRUS
AR027677A1 (en) A THERAPEUTIC PHARMACEUTICAL COMPOSITION THAT INCLUDES CAMPTOTECHINE AND CYCLOFOSPHAMIDE FOR THE TREATMENT OF CANCER
AR013498A1 (en) USE OF IFN-ALPHA AND AMANTADINE FOR THE TREATMENT OF CHRONIC HEPATITIS C USE OF IFN-ALPHA
DK1150981T3 (en) Therapeutic necleoside compound
PT1313500E (en) DALFOPRISTINE / QUINUPRISTINE ASSOCIATES WITH CEFPIROME
ECSP951438A (en) Azithromycin Controlled Release Dosage Forms
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
TH58469A3 (en) Use of Peg-IFN-alpha and ribavirin for the treatment of chronic hepatitis C
DK1311286T3 (en) Treatment of hepatitis C with thymosin and pegylated interferon
GT199500023A (en) DOSAGE FORMS OF CONTROLLED RELEASE AZITHROMYCIN
UY26735A1 (en) METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS